Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

5 million, representing the premium paid, was charged to R&D in the third quarter.

Third-quarter selling, general and administrative (SG&A) expense decreased 15.3 percent to $33.9 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of severance costs incurred in 2006 for executives of $7.1 million, partially offset by increased costs associated with the expansion of finance and accounting functions and increased professional costs related to the Company's restatement of prior periods.

2007 Financial Outlook

Par has adjusted its previously announced guidance for full-year 2007 earnings per diluted share of $1.45-$1.50 from $1.35-$1.50. Total net revenue is expected to be between $760-$780 million. SG&A is expected to be $130-$133 million, including approximately $2 million in severance costs. Research and development cost is projected to be in the range of $75-$80 million, including approximately $19 million in branded milestone payments. Total projected expenses for the full-year include approximately $18-20 million of share-based compensation and $24-$26 million of depreciation and amortization expenses. Adjusting for non-GAAP items highlighted on the summary of estimated operating results for full year 2007 at the end of this press release, full year earnings per diluted share is projected to be $1.50-$1.55.

Stock Repurchase Program

Since October 1, 2007, Par has repurchased 1,643,094 shares of its common stock at a total cost of $31.5 million. On September 28, 2007, Par announced that its Board of Directors had authorized the repurchase of up to $75 million of the Company's common stock.

Conference Call

Par has scheduled a conference call for Thursday, December 20, 2007 at 9:00 am EST to discuss results for the third quarter of 2007. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's webs
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... By Randy Dotinga ... -- Women who have the largest number of post-traumatic stress ... an addiction to food, a new study suggests. ... women overeating or becoming addicted to food. And it,s also ... experiencing trauma, PTSD, or both. Still, the research ...
(Date:9/18/2014)... 18, 2014 How much is a ... of the factors contributing to the obesity epidemic in ... single serving and how to manage portion size during ... Oct. 3 at Humility House, 755 Ohltown Road, Austintown. ... lead the informational discussion and answer questions from 12:30 ...
(Date:9/18/2014)... Texas Physical Therapy Specialists (TexPTS) is proud to ... Association (HPA) Friends and Family Golf tournament on ... tournament, which will take place at TopGolf from 9 ... through three golf challenges, “Top Scramble”, “Top Score”, and ... provided at the event and there will be open ...
(Date:9/18/2014)... Eye doctors have long known that staring ... basal tear film in the eyes to lose water and ... that staring at a computer screen can also alter the ... about computers, the tear film and dry eye for years ... (*Gray, Sarah, “Staring at Screen is Altering Your Tears, Study ...
(Date:9/18/2014)... 18, 2014 Members of United ... participating network dentists at UnitedConcordia.com, thanks to a ... company. , "Members can book an appointment with ... button located on the Find a Dentist page ... of network operations at United Concordia. "We are ...
Breaking Medicine News(10 mins):Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:HMHP Workshop Addresses Portion Control 2Health News:Texas Physical Therapy Specialists Sponsoring HPA Friends & Family Golf Tournament 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 2Health News:New Study Confirms that Staring at a Computer Screen Alters Tear Film Content and Causes Dry Eye 3Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3
... , , LEXINGTON, Ky., Sept. ... stopping in Kentucky throughout the week of September 8 - 11 ... access information on programs that provide prescription medicines for free or ... -- one of the worst rates in the nation -- the ...
... BATESVILLE, Ind., Sept. 4 Hill-Rom Holdings, Inc. (NYSE: ... $0.1025 per share. This dividend was declared by Hill-Rom,s Board of ... to shareholders of record as of September 16, 2009. , , ... is a leading worldwide manufacturer and provider of medical technologies and related ...
... , , , DETROIT, Sept. ... Daniel J. Loepp made the following statement in conjunction with the ... with a serious illness. , , Blue Cross ... to jointly announce Mr. Harwell,s retirement as Blue Cross,s health and ...
... , , , ... Dk hybrid contact lens manufacturer, recently introduced a new ... revolutionary contact lens that takes advantage of the best ... centration, stability, and all-day comfort. The patent-pending design is ...
... , NEW HAVEN, Conn., Sept. 4 ... development and commercialization of novel antibiotics for the treatment of ... has joined the company as Chief Business Officer. In his ... activities. , , Mr. Kassberg, age 49, ...
... , NEW YORK, Sept. 4 Delcath Systems, ... its proprietary treatment method for primary and metastatic cancers to the ... make a presentation to investors at the Rodman & Renshaw 11th ... Time in New York. Mr. Hobbs will review the Company,s business ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Kentucky Workers Hurt by Recession 3Health News:SynergEyes, Inc. Expands Launch of New Hybrid Contact Lens Design for Keratoconus Patients 2Health News:Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer 2
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 /PRNewswire/ ... the appointments of Dr. Ashraf Hanna , M.D., ... to its Board of Directors. Dr. Hanna is the ... Genentech and Chief Financial Officer for the Genentech Foundation, ... and Global Head of Business Development and Licensing for ...
(Date:9/18/2014)... Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage ... pain, announced today that it has appointed Mr. ... Director of Clinical Development. During his extensive ... led successful global clinical operations teams, in the US ... clinical development of numerous therapeutics and diagnostics across a ...
(Date:9/18/2014)... /CNW/ - A new expert panel report, Improving Medicines ... released today by the Council of Canadian Academies, addresses ... children. Each year about half of Canada,s ... prescription drug. Much of this prescribing is done off-label ... potential health risks. Children have historically been ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... publication in prominent peer-reviewed journal highlights,findings of ... infection, EVANSTON, Ill., March 17 ... using a,rapid molecular diagnostic test is effective ... published in the Annals of Internal Medicine,by ...
... on Track to Initiate Phase 2b in Second Quarter ... - Conference Call Tomorrow at 8:00 a.m. ... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced positive ... RDEA806, its novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients ...
Cached Medicine Technology:Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 2Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... hands play an important part in our ... and rheumatic changes can cause severe handicaps. ... the finger-joint prostheses was to produce a ... natural function as nearly possible.,The cementless RM ...
... precise control of the thigh during varus/valgus manipulation ... the proximal thigh during ACL or PCL procedures. ... on both right and left legs and may ... Holder can be used with an Arthrex tourniquet ...
... for trauma, foot and ankle or deformity ... External Fixation components are designed to reduce ... the complexity of intra-operative and post-operative frame ... and hinges eliminate the need to stock ...
Medicine Products: